South Korea Short Bowel Syndrome Market

South Korea Short Bowel Syndrome Market Size & Forecast:

• South Korea Short Bowel Syndrome Market Size 2025: USD 269.5 Million
• South Korea Short Bowel Syndrome Market Size 2033: USD 417.4 Million
• South Korea Short Bowel Syndrome Market CAGR: 5.62%
• South Korea Short Bowel Syndrome Market Segments: By Treatment Type (Parenteral Nutrition, GLP-2 Therapy, Nutritional Supplements, Intestinal Rehabilitation, Surgery, Others) | By Disease Type (Pediatric SBS, Adult SBS, Chronic SBS, Acute SBS, Others) | By Route (Oral, Injectable, Intravenous, Enteral, Others) | By End User (Hospitals, Specialty Clinics, Homecare, Research Centers, Others) 

South Korea Short Bowel Syndrome Market Summary

The South Korea Short Bowel Syndrome Market was valued at USD 269.5 Million in 2025. It is forecast to reach USD 417.4 Million by 2033. That is a CAGR of 5.62% over the period.

The South Korea Short Bowel Syndrome market kind of tackles the long-term nutritional and clinical management realities for patients who simply cannot absorb enough nutrients after extensive intestinal removal, or when they face severe intestinal conditions. In practice, this market helps healthcare teams stick with sustained survival goals, cut down on complications, and raise day to day well-being, mostly through specialized parenteral nutrition, newer biologic treatments, and coordinated home based support that actually follows the patient. Over the past three to five years, you can see the shift happening, moving away from mostly supportive nutrition handling toward approaches meant to stimulate intestinal adaptation and lessen reliance on parenteral nutrition. That change has been strengthened by wider uptake of home infusion services and more organized, value aligned treatment pathways.

Then the COVID-19 pandemic came in and bumped up investments in remote patient monitoring, and these decentralized care models too, so hospitals can shorten prolonged inpatient stays. Now, as clinicians lean harder into therapies that aim to reduce readmissions or hospitalization numbers and also lower long term care expenses, adoption is widening. That gives better revenue chances not only for pharmaceutical companies, but also for nutrition providers and for the specialized healthcare service groups that run these programs.

Key Market Insights

• In 2025, the Seoul Capital Area kind of dominated the South Korea Short Bowel Syndrome market with around 58% market share , backed by top-tier tertiary hospitals and more specialized gastrointestinal centers, so it looks pretty solid there.
• Meanwhile Busan and the Gyeongsang regions are seen as the fastest mover through 2032, driven by broader referral pathways , plus better access to home parenteral nutrition services, in other words more people can actually reach treatment.
• On the therapy side, biologic therapies took the lead, making up the largest portion at roughly 46% in 2025, which points to wider use of GLP-2 analog based treatment protocols.
• Parenteral nutrition stayed as the second-largest segment, still bringing in strong revenue thanks to ongoing nutritional assistance for severe SBS patients, over long stretches.
• The home infusion and integrated nutritional management area is expected to grow the quickest between 2025 and 2032, supported by initiatives focused on healthcare cost optimization, and yeah that matters in practice.
• For patient groups, adult Short Bowel Syndrome treatment held the largest share, at nearly 67% , which reflects higher incidence after complex gastrointestinal surgeries.
• For applications, pediatric intestinal rehabilitation programs are forecasted to expand faster than others, supported by progress in multidisciplinary neonatal and pediatric care.
• When it comes to end users, tertiary hospitals kept the biggest share, crossing 62% in 2025, mostly because complex patient handling needs specialist know-how.
• Finally, home healthcare providers are emerging as the fastest-growing end-user category , helped by reimbursement improvements and remote clinical monitoring, so the trend is really toward at-home support.

What are the Key Drivers, Restraints, and Opportunities in the South Korea Short Bowel Syndrome Market?

The most powerful driver for market expansion is the clinical shift toward disease-modifying biologic therapies that help reduce long-term reliance on parenteral nutrition, in a sort of quieter but steady way. As real-world outcomes stay positive and treatment guidance gets updated, physician confidence has broadened a lot, so clinicians are willing to start earlier for patients who qualify. Meanwhile, South Korea’s more mature tertiary hospital network has kept expanding multidisciplinary intestinal rehabilitation programs, which makes it possible to coordinate care across gastroenterologists, nutrition specialists , surgeons, and pharmacists. With this kind of integrated model, patient outcomes tend to improve, hospitalization shows a lower frequency, and new revenue avenues can appear for pharmaceutical manufacturers, infusion providers, and specialized clinical service organizations.

Still, the largest structural obstacle is the treatment price connected with biologic therapies and the need for prolonged nutritional support. Short Bowel Syndrome involves a relatively limited patient group, so manufacturers struggle to gain strong economies of scale while per-person healthcare spending rises. On top of that, complicated reimbursement reviews plus tight eligibility rules can slow down when therapy actually begins. Because of these limits, overall adoption stays suppressed, and even with clear clinical advantages, the market may not fully capture the pharmaceutical revenue potential.

The next phase in market expansion is probably going to come from digitally enabled home intestinal rehabilitation programs, in a way that feels more seamless, not just a small upgrade. With remote nutrition monitoring , connected infusion devices, and AI supported clinical decision platforms physicians can fine tune nutritional regimens while cutting down on those unnecessary hospital visits. And if home healthcare infrastructure keeps getting backed, say through continued investment, then along with personalized medicine and biomarker guided treatment selection , there are real openings for healthcare providers as well as innovative therapy developers to support longer term patient care across South Korea.

What Has the Impact of Artificial Intelligence Been on the South Korea Short Bowel Syndrome Market?

Artificial intelligence is slowly but surely reshaping clinical management across the South Korea Short Bowel Syndrome Market, mostly by making nutritional optimization feel more precise, helping with treatment planning, and keeping a steadier watch on patients over time. In more and more hospitals, AI assisted clinical decision support tools are being used to sort through lab results, track body weight movement, review fluid balance, check liver function, and confirm nutritional intake. In practice, these tools handle the routine checks that once took a lot of hands on manual review, so clinicians can revise parenteral nutrition formulations faster, and in a more consistent way than before.

Beyond that, machine learning is used for predictive care, catching earlier signals that a patient might be more likely to face catheter related bloodstream infections, dehydration liver issues, or even hospital readmission. If the risk is recognized sooner, clinicians can step in earlier with more proactive actions which helps lower avoidable complications, while also improving treatment continuity, that part matters. Remote monitoring solutions linked with connected infusion devices also help a lot with outpatient follow ups, since patients tend to stick closer to the plan and there are fewer reasons for unnecessary inpatient admissions.

Digital technologies meanwhile boost operational efficiency, for example by streamlining inventory management of specialized nutrition products and by forecasting patient specific nutritional needs, almost like it learns individual patterns over time. Hospitals frequently note better use of resources, quicker clinical review cycles, and improved continuity of care when digital health platforms are integrated across workflows.

Still, AI adoption has friction. The big obstacles are high implementation costs, clinical data that is scattered across systems, and the fact that there are not that many Short Bowel Syndrome patients, meaning algorithm training can be somewhat limited. Because of these constraints, predictive accuracy may not transfer equally well across different patient groups, and that also slows wider deployment of advanced AI driven care solutions.

Key Market Trends

• Since 2021 , biologic therapies have shifted the whole treatment strategy, moving way past mere nutritional support, toward intestinal adaptation and less reliance on parenteral nutrition , which is a big thing.
• After the pandemic, home parenteral nutrition programs have expanded , mostly because hospitals started pushing harder for long-term outpatient care, and they shortened inpatient stays, a bit.
• At the same time, digital patient monitoring platforms have been slowly built into intestinal rehabilitation programs, and that helped with treatment adherence, plus clinical follow up , too.
• Pharmaceutical companies also leaned into partnerships with tertiary hospitals , to push biologic adoption faster and to build more solid real-world clinical evidence , in practice.
• Personalized nutritional management got more traction , especially with biomarker guided treatment planning and multidisciplinary coordination across specialized centers, working together.
• Domestic healthcare providers have upped investment in connected infusion technologies , these things help with safety monitoring and they optimize ongoing nutritional therapy.
• Manufacturers went beyond just the pharmaceuticals , adding patient education, home healthcare coordination, and remote clinical assistance as part of support services.
• Regulatory pressure on healthcare efficiency encouraged broader use of outpatient nutritional management models, aiming to cut hospitalization costs, while still improving patient outcomes , overall.
• And honestly the competition now feels less about a single product , more about full care ecosystems that combine biologics, specialized nutrition products, digital monitoring, and multidisciplinary rehabilitation services.

South Korea Short Bowel Syndrome Market Segmentation

By Treatment Type :

Parenteral Nutrition stays as a necessary treatment approach for patients who can’t absorb enough nutrients from the digestive tract, so they kind of miss the usual intake. GLP-2 therapy works alongside the body’s natural process of intestinal adaptation, and it can help lower dependence on intravenous nutrition, when the patient fits the criteria. Nutritional supplements give extra support too, based on each person's specific nutritional requirements.

Intestinal rehabilitation is more of a combination: nutritional management with medical care, plus continuous monitoring in order to improve digestive function gradually. Surgery is usually kept as an option only when treatment by itself does not bring enough improvement , or if complications show up and need intervention. Beyond that there are additional treatment options, like supportive therapies that are adjusted to the individual clinical situation and the intended recovery outcomes.

By Disease Type :

Pediatric SBS covers kids who end up with the condition due to inherited, congenital disorders , intestinal injury , or surgery done very early in life. Adult SBS usually comes from a large bowel removal after things like Crohn’s disease, trauma, cancer therapy , or other gut related problems. Chronic SBS means ongoing, continuous long term management , with nutrition and medication support kept in place for a while.

Acute SBS points to the early period after intestinal surgery , where getting nutritional stabilization right becomes the main focus. There are also other, rarer disease groupings, with clinical signs that do not fit the usual pattern,so they need more specialized treatment plans. Each disease type then takes its own care route, depending on how severe it is, how much bowel function is still left, and the overall health situation of the person.

By Route :

Oral management works well for patients who have enough intestinal absorption, and it usually contains medications along with nutritional supplements, sort of in a bundled way. For injectable therapies, the main focus is biologic medicines, which are given with clinical oversight, not at home casually. Intravenous delivery still stays crucial, especially for parenteral nutrition, and for fluid replacement in people with serious limits in nutrient uptake.

Enteral feeding provides nutrition right into the gastrointestinal tract via feeding tubes, whenever the digestive process can still take in at least part of the nutrients. Beyond that, there are other administration routes too, using specialized delivery approaches that are picked based on the patient status, the treatment goals, and the physician’s recommendations for chronic or long-term disease control.

By End User :

Hospitals are still the key treatment setting, because teams working across disciplines deliver diagnosis, surgical care, dietary guidance , and continuous follow ups. Specialty clinics tend to handle more focused gastrointestinal care, arranging follow-up treatment, plus personalized nutritional planning, especially for stable patients who need regular evaluation.

Homecare services keep growing too, as long-term parenteral nutrition and remote clinical monitoring make it possible to deliver care beyond the hospital walls. Research centers also matter, mainly by testing new therapies, refining clinical protocols, and exploring fresh treatment paths. Other end users, like rehabilitation facilities and healthcare organizations, help run specialized patient management and ongoing clinical care.

What are the Key Use Cases Driving the South Korea Short Bowel Syndrome Market?

The main use case that’s really pushing the South Korea Short Bowel Syndrome Market seems to be long-term nutritional management for people with severe intestinal failure after bowel resection. In practice hospitals end up pulling the most treatment demand, because the tough cases need ongoing parenteral nutrition, plus specialist monitoring , and a kind of coordinated care approach so complications can be avoided while nutritional stability stays in place.

People are also widening the applications, moving toward home-based nutritional therapy , and using multidisciplinary intestinal rehabilitation programs for patients who are stable enough to transition out of inpatient care. Specialty clinics and homecare providers are leaning into these care models to help shorten hospital days, keep treatment going more smoothly, and bring down long term healthcare expenses , as long as clinical outcomes don’t take a hit.

On the newer side, emerging use cases include more personalized biologic style therapy that’s guided by how the patient responds, along with digital remote monitoring platforms that enable individualized nutritional adjustments. Research centers are meanwhile testing advanced regenerative medicine and intestinal adaptation therapies. If these efforts work as expected, they could strengthen longer term recovery and reduce the reliance on lifelong nutritional support during the forecast period.

Which Regions are Driving the South Korea Short Bowel Syndrome Market Growth?

The Seoul Capital Area still stays as the biggest regional market, because it kinda gathers the country’s leading tertiary hospitals, academic medical centers, and also specialist gastroenterology departments. Thanks to strong healthcare infrastructure , patients can move fast from diagnosis to multidisciplinary treatment, plus there’s easier access to advanced biologic therapies for tough Short Bowel Syndrome cases. On top of that, national reimbursement support for specialized treatment keeps patient access solid right there. Hospitals , research institutions , and pharmaceutical companies keep working closely together, so clinical innovation stays active, and market leadership stays there as well.

Meanwhile the Busan and Gyeongsang region contributes a steady stream of market revenue, mostly due to a well-developed healthcare network and continuing investment in regional referral hospitals. Compared with the Seoul Capital Area, the growth story here is less about major academic center concentration and more about widening access to specialized care, step by step. Healthcare providers are also pushing harder on intestinal rehabilitation services and long-term nutritional management programs for people who need ongoing treatment. With relatively stable healthcare spending and gradual expansion of specialist services, this area remains a dependable part of overall market growth.

In the Chungcheong and Jeolla areas, the fastest growth through 2033 is expected to show up as the whole regional healthcare capacity continues getting better . Newer investments going into hospital modernization, digital health platforms, and home based clinical services are widening treatment access, even outside the biggest metro zones. With more remote patient monitoring being adopted, plus multidisciplinary outpatient care offered more often, treatment obstacles for people needing long-term nutritional support are starting to ease . Overall, this situation opens up interesting momentum for pharmaceutical companies, nutrition providers, and home healthcare organizations that are looking at regional expansion during the 2026–2033 window.

Who are the Key Players in the South Korea Short Bowel Syndrome Market and How Do They Compete?

Competition in the South Korea Short Bowel Syndrome market is sort of moderately concentrated , with a mix of global pharmaceutical players and specialized nutrition providers holding a meaningful portion of treatment revenue. The real fight seems to be about clinical effectiveness, but also about long term patient support and that specialized nutritional products angle. Beyond that , companies try to work closely with hospitals that handle complicated intestinal disorders. A lot of effort goes into physician education as well, plus expanding reimbursement access, and then backing multidisciplinary treatment programs that are supposed to improve long run patient outcomes , kind of on purpose rather than by luck.

Takeda Pharmaceutical sets itself apart by leaning into advanced biologic therapy aimed at lowering dependence on long term parenteral nutrition. It keeps investing in clinical evidence, and stays active with physicians, while building partnerships with major healthcare institutions. That combo, at least in practice , helps broaden treatment adoption across South Korea. Zealand Pharma, on the other hand, is more centered on peptide based therapy innovation and it keeps pushing development collaborations that could widen future intestinal rehabilitation opportunities.

Baxter International tends to compete with a broader parenteral nutrition portfolio, backed by solid hospital distribution plus home infusion capabilities. Fresenius Kabi bundles specialized clinical nutrition products with integrated infusion technologies, so providers can manage complex nutritional needs more efficiently. B. Braun expands its role by supplying infusion systems, nutritional products, and clinical support services , which helps keep treatment continuity steady across both hospital settings and homecare environments.

Company List

• Takeda
• Merck
• Fresenius Kabi
• Baxter
• Nestlé Health Science
• Pfizer
• Abbott
• B. Braun
• Nutricia
• Otsuka
• Eisai
• Roche
• Sanofi
• Novartis
• Hanmi Pharma 

Recent Development News

In June 2025, Zealand Pharma announced submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for glepaglutide, a twice-weekly GLP-2 therapy for short bowel syndrome. The filing marked an important regulatory milestone that could expand treatment options and strengthen future competition in the global and South Korean Short Bowel Syndrome market. Sourcehttps://www.globenewswire.com/

In May 2026, Takeda Canada announced reimbursement approval for REVESTIVE (teduglutide) through BC PharmaCare for eligible pediatric and adult patients with short bowel syndrome dependent on parenteral support. The reimbursement expands patient access to GLP-2 therapy and highlights continued investment in advanced SBS treatment pathways that can influence adoption across international markets. Sourcehttps://www.takeda.com/

What Strategic Insights Define the Future of the South Korea Short Bowel Syndrome Market?

The South Korea Short Bowel Syndrome Market is expected to keep moving, in a pretty steady way, toward a more integrated disease management approach that leans on biologic therapies, home-based nutritional support, and digital patient monitoring over the next five to seven years. The real driver here is that the healthcare system will keep pushing to reduce long-term hospitalization while also lifting patient outcomes via coordinated, individualized care. And as reimbursement rules gradually catch up and start recognizing the value of advanced therapies, especially those linked with fewer complication rates, uptake should expand beyond just the big tertiary hospitals, kind of spreading outward.

There’s also a risk that doesn’t show up as clearly at first glance. The market can become reliant on a small set of high-value biologic products and a limited circle of specialized suppliers. So if there are delays in regulatory approvals, hiccups during pricing talks, or even supply disruptions, patient access could get constrained. That would slow revenue growth even if clinical demand stays strong. Meanwhile, AI-enabled nutritional optimization platforms and remote intestinal rehabilitation programs are starting to look like a real opportunity, particularly as regional hospitals upgrade their digital healthcare capabilities. Firms that put money in early on integrated treatment ecosystems—combining biologic therapies with homecare services and digital monitoring—should end up better placed to maintain sustainable competitive momentum across the full forecast window.

South Korea Short Bowel Syndrome Market Report Segmentation

By Treatment Type

• Parenteral Nutrition
• GLP-2 Therapy
• Nutritional Supplements
• Intestinal Rehabilitation
• Surgery

By Disease Type

• Pediatric SBS
• Adult SBS
• Chronic SBS
• Acute SBS

By Route

• Oral
• Injectable
• Intravenous
• Enteral

By End User

• Hospitals
• Specialty Clinics
• Homecare
• Research Centers